Oculis Holding AG Warrants
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-opht… Read more
Oculis Holding AG Warrants (OCSAW) - Net Assets
Latest net assets as of June 2024: $112.83 Million USD
Based on the latest financial reports, Oculis Holding AG Warrants (OCSAW) has net assets worth $112.83 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($138.73 Million) and total liabilities ($25.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $112.83 Million |
| % of Total Assets | 81.33% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Oculis Holding AG Warrants - Net Assets Trend (2020–2023)
This chart illustrates how Oculis Holding AG Warrants's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oculis Holding AG Warrants (2020–2023)
The table below shows the annual net assets of Oculis Holding AG Warrants from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $93.73 Million | +195.65% |
| 2022-12-31 | $-97.99 Million | -60.76% |
| 2021-12-31 | $-60.95 Million | -39.63% |
| 2020-12-31 | $-43.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oculis Holding AG Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14605200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $293.51 Million | 313.15% |
| Total Equity | $93.73 Million | 100.00% |
Oculis Holding AG Warrants Competitors by Market Cap
The table below lists competitors of Oculis Holding AG Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Flamemaster Corporation
PINK:FAME
|
$161.30K |
|
LOGAN RIDGE FIN. DL-01
F:0XL0
|
$161.59K |
|
Green Cross Holdings Corp. Pfd. Series 2
KQ:005257
|
$161.75K |
|
rad Fic Firf Invest Infra Cdi Cp Resp Ltda
SA:BINC11
|
$161.81K |
|
APXR11
SA:APXR11
|
$161.21K |
|
Federal Home Loan Mortgage Corporation PFD 5.1% SAL
OTCQB:FREJO
|
$161.20K |
|
Target Global Acquisition I Corp. Warrant
NASDAQ:TGAAW
|
$161.18K |
|
Wealth In HP InvLaDK OblAkk-KL
CO:WEIHPILDKOAKKKL
|
$161.11K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oculis Holding AG Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -97,991,000 to 93,728,000, a change of 191,719,000.
- Net loss of 88,802,000 reduced equity.
- New share issuances of 135,615,000 increased equity.
- Other factors increased equity by 144,906,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.80 Million | -94.74% |
| Share Issuances | $135.62 Million | +144.69% |
| Other Changes | $144.91 Million | +154.6% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Oculis Holding AG Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1.33 | $16.43 | x |
| 2021-12-31 | $-1.86 | $16.43 | x |
| 2022-12-31 | $-2.99 | $16.43 | x |
| 2023-12-31 | $2.56 | $16.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oculis Holding AG Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.74%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-94.74%) is below the historical average (-23.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.51 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.46 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.90 Million |
| 2023 | -94.74% | 0.00% | 0.00x | 1.22x | $-98.17 Million |
Industry Comparison
This section compares Oculis Holding AG Warrants's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oculis Holding AG Warrants (OCSAW) | $112.83 Million | 0.00% | 0.23x | $161.26K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |